Aligos Therapeutics Inc (ALGS)

NASDAQ
26.98
-1.50(-5.27%)
  • Volume:
    181,105
  • Bid/Ask:
    22.01/33.94
  • Day's Range:
    26.68 - 28.90

ALGS Overview

Prev. Close
26.98
Day's Range
26.68-28.9
Revenue
910K
Open
28.08
52 wk Range
12.82-37.51
EPS
-
Volume
181,105
Market Cap
1.11B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
77,346
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
41,246,028
Next Earnings Date
Sep 01, 2021
What is your sentiment on Aligos Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Aligos Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellNeutralStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Buy
SummaryStrong SellStrong SellStrong SellNeutralStrong Buy

Aligos Therapeutics Inc Company Profile

Aligos Therapeutics Inc Company Profile

Employees
69

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). It developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The Company's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

Read More
  • Nobody here yet?
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.